Comment
doi: 10.1016/S1470-2045(18)30411-X.
Epub 2018 Jun 1.
More convenient proteasome inhibition for improved outcomes
Affiliations
- PMID: 29866476
- DOI: 10.1016/S1470-2045(18)30411-X
Item in Clipboard
Comment
More convenient proteasome inhibition for improved outcomes
Lancet Oncol.
2018 Jul.
Free article
No abstract available
Comment on
-
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.Lancet Oncol. 2018 Jul;19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1. Epub 2018 Jun 1. Lancet Oncol. 2018. PMID: 29866475 Clinical Trial.
Similar articles
-
The ubiquitin-proteasome-system.Biochim Biophys Acta. 2014 Jan;1843(1):1. doi: 10.1016/j.bbamcr.2013.09.009. Epub 2013 Sep 19. Biochim Biophys Acta. 2014. PMID: 24055503 No abstract available.
-
Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits.Elife. 2015 Sep 1;4:e08153. doi: 10.7554/eLife.08153. Elife. 2015. PMID: 26327694 Free PMC article.
-
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.BMC Cancer. 2016 Mar 24;16:247. doi: 10.1186/s12885-016-2285-2. BMC Cancer. 2016. PMID: 27012957 Free PMC article.
-
Proteasome inhibitors for multiple myeloma.Jpn J Clin Oncol. 2018 Sep 1;48(9):785-793. doi: 10.1093/jjco/hyy108. Jpn J Clin Oncol. 2018. PMID: 30102324 Review.
-
The proteasome and proteasome inhibitors in multiple myeloma.Cancer Metastasis Rev. 2017 Dec;36(4):561-584. doi: 10.1007/s10555-017-9707-8. Cancer Metastasis Rev. 2017. PMID: 29196868 Review.
Cited by
-
Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carthadex (KTd)-trial update?Haematologica. 2019 Nov;104(11):2128-2131. doi: 10.3324/haematol.2019.228684. Haematologica. 2019. PMID: 31666342 Free PMC article. No abstract available.
-
Ixazomib-lenalidomid-dexamethasone (IRd) in relapsed refractory multiple myeloma (RRMM)-multicenter real-world analysis from Germany and comparative review of the literature.Ann Hematol. 2025 Jul;104(7):3713-3722. doi: 10.1007/s00277-025-06441-8. Epub 2025 Jun 5. Ann Hematol. 2025. PMID: 40471328 Free PMC article. Review.
-
High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex.Haematologica. 2023 Jun 1;108(6):1628-1639. doi: 10.3324/haematol.2022.282225. Haematologica. 2023. PMID: 36727403 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
